Microdosing
Start low, go slow. A calm, medically supervised path to steadier energy, fewer cravings, and long‑term metabolic health.
Get started
Provide information about your goals and medical history to fuel your metabolic health assessment.
A licensed healthcare provider carefully reviews your health information and determines whether treatment is appropriate.
.webp)
Providers may recommend prescription treatments from licensed pharmacies.
.webp)
Stay connected with your clinician as your plan evolves.
Provide information about your goals and medical history to fuel your metabolic health assessment.
A licensed healthcare provider carefully reviews each case and determines whether treatment is appropriate.
Providers may recommend prescription treatments from licensed pharmacies.
Stay connected with your clinician as your plan evolves.
A clinician-guided wellbeing program focused on mood, focus, and routines—using approaches that are legal and medically appropriate where you live.
Legality varies by location and treatment type. We only provide care that complies with local regulations and clinician licensing.
Eligibility depends on mental-health history, current medications, and goals. Some psychiatric histories may make microdosing inappropriate.
Medical intake and clinician review, a personalized plan when appropriate, and follow‑ups to monitor response and safety.
A microdose should not cause impairment. If you feel impaired or uncomfortable, stop and contact your care team.
Many people evaluate changes over several weeks. Effects are subtle for some people and not guaranteed.
Possible effects include anxiety, headache, sleep disruption, or GI upset. These are often related to dose or timing and can improve with adjustments.
Sometimes, but interactions and risks vary. Share your full medication list so your clinician can advise safely.
Avoid combining with recreational substances and avoid major medication changes without clinician guidance.
This is not a replacement for psychotherapy. If therapy is a better fit, we’ll recommend appropriate resources.
Pause and contact your care team. If you have severe anxiety, suicidal thoughts, hallucinations, or safety concerns, seek urgent help immediately.
Yes. You can stop at any time; let your clinician know so they can guide a safe transition.
Nausea is one of the most common early side effects people report on semaglutide-based therapy. The good news: for many patients, it improves as the body adjusts—especially when you use a few practical habits.
Eat smaller meals, slow down, and stop at “comfortably satisfied.” Overeating can feel worse when digestion is slower.
Dehydration can worsen nausea and fatigue. Sip water throughout the day. If your clinician recommends electrolytes, use them strategically.
Many people tolerate bland, protein-forward foods better during the adjustment phase: yogurt, eggs, soups, cooked vegetables, toast, rice, or smoothies (if tolerated).
Very fatty meals, fried foods, and heavy desserts can worsen nausea in some people. If symptoms spike after certain foods, reduce them temporarily.
Some patients find nausea is more noticeable in a predictable window after dosing. Keep meals lighter during that window and avoid large, rich meals.
Severe or persistent vomiting, inability to keep fluids down, or signs of dehydration require medical attention. Don’t self-adjust treatment without clinician input.
A GLP-1 plateau can feel discouraging, but it’s often a normal checkpoint, not a failure.
As weight decreases, your body adapts. Energy needs can change, and routines that worked early may become less effective. Plateaus can also reflect inconsistent nutrition (especially protein), reduced movement, stress, or sleep disruption.
Treat a plateau like feedback. It’s telling you what needs refinement: habits, support, expectations, or clinical oversight.
Semaglutide-based therapy may be prescribed for chronic weight management in appropriate patients as part of a broader program that includes nutrition and physical activity.
A licensed clinician must screen for contraindications and major risk factors. Patients should disclose full medical history, medications, and family history. If a patient has concerning symptoms (for example, a new neck lump, hoarseness, trouble swallowing, or shortness of breath), they should seek medical evaluation promptly.
If the medication is compounded, disclose clearly: compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality before marketing.
Patients should also be warned not to combine semaglutide with other GLP-1/GIP medicines unless directed by a clinician, and that safety with other weight-loss products may not be established.
List red-flag symptoms (severe/persistent vomiting, dehydration signs, severe abdominal pain, allergic reactions) and provide a clear emergency instruction.
If medication is provided in a vial, patients must measure doses accurately. Confusion between measurement units is a known risk with compounded injectables. Patients should follow clinician/pharmacy instructions and contact the care team if uncertain.
.webp)
.webp)